Key Statistics

  • Affects 0.5–1% of the population
  • Women affected twice as often as men
  • Mean duration of 2–5 years; some cases persist longer
  • Up to 50% of CSU cases have autoimmune basis
  • Antihistamines effective in only 50% of patients at standard doses

What Is Chronic Urticaria?

Chronic urticaria (CU) is defined as the recurrence of transient, itchy wheals (hives), angioedema (deep tissue swelling), or both for more than six weeks. Chronic spontaneous urticaria (CSU) occurs without an identifiable external trigger, while chronic inducible urticaria (CIndU) is triggered by specific physical stimuli such as pressure, cold, heat, or vibration.1

While often viewed purely as a skin condition, chronic urticaria has significant systemic implications. The intense itching, unpredictable flares, associated pain from angioedema, and sleep disruption contribute to a quality-of-life burden comparable to coronary artery disease. Many patients with CSU also experience chronic pain conditions, fatigue, and psychological distress, reflecting shared immune-mediated and neuroimmune pathways.

Symptoms and Clinical Features

  • Wheals (hives): Raised, erythematous, pruritic plaques that appear and resolve within 24 hours without bruising. Individual wheals last less than 24 hours but new ones continually appear
  • Angioedema: Deeper swelling of subcutaneous or submucosal tissues, commonly affecting eyelids, lips, tongue, hands, feet, and genitalia. Occurs in up to 40% of CSU patients and can be painful
  • Intense pruritus: Itching can be debilitating, disrupting sleep, concentration, and daily activities
  • Pain and burning: Some patients report painful urticaria, particularly with pressure-induced variants and angioedema
  • Fatigue: Chronic sleep disruption from nocturnal itching leads to profound fatigue and impaired cognitive function
  • Psychological impact: Anxiety, depression, social withdrawal, and reduced quality of life are well-documented

Causes and Pathophysiology

CSU involves mast cell degranulation in the skin with release of histamine and other inflammatory mediators. The triggers for this mast cell activation include autoimmune mechanisms (type I autoimmunity with IgE autoantibodies against thyroid peroxidase or IL-24, and type IIb autoimmunity with IgG autoantibodies against the high-affinity IgE receptor FcεRI or IgE itself), mast cell intrinsic defects, and unknown factors.2

CSU frequently coexists with autoimmune thyroid disease, and patients have higher rates of other autoimmune conditions including vitiligo, rheumatoid arthritis, type 1 diabetes, and celiac disease. This autoimmune clustering suggests shared genetic susceptibility and immune dysregulation. Up to 30–50% of CSU patients test positive for the autologous serum skin test or basophil activation assays, indicating functional autoantibodies.

Diagnosis and Workup

Diagnosis is primarily clinical, based on the presence of wheals and/or angioedema recurring for more than six weeks. Recommended baseline investigations include complete blood count with differential, C-reactive protein or ESR, and thyroid function with thyroid autoantibodies. Extended workup may include total IgE, autologous serum skin test, tryptase levels, complement studies, and screening for infections (H. pylori, hepatitis). The Urticaria Activity Score over 7 days (UAS7) is the validated tool for disease severity assessment.3

Treatment Guidelines

Step 1: Second-Generation Antihistamines

Standard-dose non-sedating H1-antihistamines (cetirizine, loratadine, fexofenadine, bilastine, or desloratadine) are first-line therapy. Taken daily rather than on-demand.

Step 2: Updosing Antihistamines

If symptoms persist after 2–4 weeks, guidelines recommend increasing the dose of second-generation antihistamines up to four times the standard dose. This is effective in an additional 15–25% of patients.

Step 3: Omalizumab (Xolair)

Anti-IgE monoclonal antibody given as subcutaneous injections every 4 weeks. Omalizumab is effective in approximately 65–80% of antihistamine-refractory CSU patients, with some experiencing complete remission.4

Step 4: Cyclosporine or Other Immunosuppressants

For patients who fail omalizumab, cyclosporine A is an off-label option with demonstrated efficacy. Other options under investigation include dupilumab, ligelizumab, and BTK inhibitors.

Connection to Chronic Pain

Chronic urticaria intersects with chronic pain through several mechanisms. Angioedema episodes can cause significant tissue pain. Mast cell mediators including histamine, prostaglandins, and cytokines activate pain pathways. Chronic inflammation and immune dysregulation contribute to central sensitization. Sleep disruption from nocturnal itching lowers pain thresholds. Many patients with CSU have comorbid fibromyalgia, chronic fatigue syndrome, or other pain conditions, and addressing the urticaria component often improves overall pain burden.

Frequently Asked Questions

Is chronic urticaria an allergy?

Usually not. Unlike acute urticaria which can be allergic, chronic spontaneous urticaria is most often autoimmune or idiopathic in origin. Allergy testing is generally not helpful unless a specific trigger is suspected.

Will my chronic urticaria ever go away?

CSU often follows a relapsing-remitting course. About 30–50% of patients achieve remission within 1–3 years, and many more within 5 years. However, some patients experience a chronic course lasting decades.

Are there dietary changes that help?

While food allergies rarely cause CSU, some patients benefit from a low-pseudoallergen diet or avoidance of histamine-rich foods. Evidence is limited, and dietary changes should be guided by a specialist to avoid unnecessary restriction.

Can stress make my hives worse?

Yes. Psychological stress is a well-documented trigger for CSU flares. Stress management techniques, adequate sleep, and psychological support can complement medical treatment.

References

  1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766.
  2. Kolkhir P, Munoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819–1831.
  3. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test. J Allergy Clin Immunol. 2014;133(5):1365–1372.
  4. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935.

Related Resources